Abstract

BackgroundConflicting data exist on the role of pulmonary dendritic cells (DCs) and their maturation in patients with chronic obstructive pulmonary disease (COPD). Herein, we investigated whether disease severity and smoking status could affect the distribution and maturation of DCs in lung tissues of patients undergoing elective pneumectomy or lobectomy for suspected primary lung cancer.Materials and MethodsA total of 75 consecutive patients were included. Spirometry testing was used to identify COPD. Lung parenchyma sections anatomically distant from the primary lesion were examined. We used flow cytometry to identify different DCs subtypes—including BDCA1-positive myeloid DCs (mDCs), BDCA3-positive mDCs, and plasmacytoid DCs (pDCs)—and determine their maturation markers (CD40, CD80, CD83, and CD86) in all participants. We also identified follicular DCs (fDCs), Langerhans DCs (LDCs), and pDCs in 42 patients by immunohistochemistry.ResultsCOPD was diagnosed in 43 patients (16 current smokers and 27 former smokers), whereas the remaining 32 subjects were classified as non-COPD (11 current smokers, 13 former smokers, and 8 never smokers). The number and maturation of DCs did not differ significantly between COPD and non-COPD patients. However, the results of flow cytometry indicated that maturation markers CD40 and CD83 of BDCA1-positive mDCs were significantly decreased in smokers than in non-smokers (P = 0.023 and 0.013, respectively). Immunohistochemistry also revealed a lower number of LDCs in COPD patients than in non-COPD subjects.ConclusionsCigarette smoke, rather than airflow limitation, is the main determinant of impaired DCs maturation in the lung.

Highlights

  • Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease of the lungs characterized by progressive airflow limitation and destruction of the lung parenchyma.[1]

  • The results of flow cytometry indicated that maturation markers CD40 and CD83 of BDCA1-positive myeloid DCs (mDCs) were significantly decreased in smokers than in non-smokers (P = 0.023 and 0.013, respectively)

  • Several research groups have identified different subsets of Dendritic cells (DCs) in the human lung, mainly using antibodies raised against epitopes present on circulating blood DCs, including Blood Dendritic Cell Antigen (BDCA) 1–3 and CD11.[5]. A distinction between myeloid DCs and plasmocytoid DCs has been proposed

Read more

Summary

Introduction

Chronic obstructive pulmonary disease (COPD) is a complex chronic inflammatory disease of the lungs characterized by progressive airflow limitation and destruction of the lung parenchyma.[1]. Dendritic cells (DCs) are a heterogeneous population of antigen-presenting cells.[4] The classification of DCs in COPD remains controversial. The mDCs subset can be further divided into the type 1 mDCs (mDCs1) and type 2 mDCs (mDCs2) subpopulations.[6] no data obtained by flow cytometry are currently available on pulmonary tissue resident mDCs, such as Langerhans-type DCs (LDCs) and follicular DCs (fDCs).[7]. Conflicting data exist on the role of pulmonary dendritic cells (DCs) and their maturation in patients with chronic obstructive pulmonary disease (COPD). We investigated whether disease severity and smoking status could affect the distribution and maturation of DCs in lung tissues of patients undergoing elective pneumectomy or lobectomy for suspected primary lung cancer

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call